MAP3K8 and metastatic melanoma: Further mechanisms of developing resistance have been described including increased COT expression (a gene transcribed from MAP3K8 which acts as a MAPK agonist) which increases phosphorylation of ERK and MEK in a RAF-independent fashion leading to PLX4720 resistance in metastatic melanoma cell lines (86).